JP2020078534A - Radioactive medicine administration device - Google Patents

Abstract

To provide a radioactive medicine administration device that has downsized external dimensions and has advantage for saving a space required for installing the device.SOLUTION: A radioactive medicine administration device comprises: a container holder 122 for holding a shield container 5 for a radiopharmaceutical 27; a passage constituting member arrangement part 14 to which a passage switching members 33a, 33b, 33c, a first syringe 36a, a second syringe 36b, a saline passage 31a, a radioactive passage 31b, and an air-vented filter 32 that constitute part of a passage connected to a vial 7 stored in the container holder 122 are fitted; a shield member 21 against radioactive radiation discharged from the radiopharmaceutical; and a device housing 20 for the shield member. The shield member 21 has a shield wall 21g having a top surface having a part lower than the other parts that corresponds to sizes of passage constituting members. The radioactive passage 31b is loosely inserted outside the shield member 21 and above the shield wall 21g.SELECTED DRAWING: Figure 3

Description

  The present invention relates to a radiopharmaceutical administration device that administers a radiopharmaceutical into a living body.

  It is known that a radiopharmaceutical is decomposed with time according to an inherent half-life of a radionuclide contained in the radiopharmaceutical and emits radiation at that time. For this reason, it is known that the operation of handling a radiopharmaceutical is performed using an automatic administration device in order to prevent the operator from being exposed to radiation. Such a radiopharmaceutical administration device is described in Patent Document 1, for example. The radiopharmaceutical administration device described in Patent Document 1 is provided on a container arrangement part in which a shielded container containing a radiopharmaceutical contained in a vial is arranged, an infusion tube forming a flow path of the radiopharmaceutical, and a flow path. The syringe and the like for extracting the radiopharmaceutical from the flow path switching member and the shielding container and administering it to the living body are provided. These components are covered with a radiation shielding member.

JP 2006-15055 A

However, the radiation shielding member of the radiopharmaceutical administration device described in Patent Document 1 has a substantially rectangular parallelepiped shape in appearance, and the shielding space formed therein also has a substantially rectangular parallelepiped shape. Such a radiation shielding member is designed in accordance with the one having a large space required for installation among the above-mentioned flow path switching member, syringe and the like arranged inside. For this reason, in the shielded space, there may be a space (excess space) that is not used for the installation of the member around the member having a relatively small installation space. As described above, the radiopharmaceutical administration device described in Patent Document 1 in which an extra space is generated in the device is disadvantageous in downsizing the device, and there is room for further reducing the installation space.
The present invention has been made in view of the above circumstances, and relates to a radiopharmaceutical administration device that is advantageous in reducing the external dimensions thereof and saving the space required for installation.

  The radiopharmaceutical administration device of the present invention is a radiopharmaceutical administration device for administering a radiopharmaceutical to a living body, comprising a container holding part for holding a shielding container accommodating the drug container of the radiopharmaceutical, and the inside of the container holding part. A structure mounting portion to which a plurality of flow path constituting members constituting a part of the flow path connected to the drug container housed in, and at least a part of the container holding portion and the structure mounting portion are covered. A shielding member that shields radiation emitted from the radiopharmaceutical and an apparatus housing that covers at least a part of the shielding member, and the shielding member has a part of the upper surface in the installation direction other than the upper surface. And a lower insertion area in which the flow path drawn out from the shielding member is loosely inserted outside the shielding area covered by the shielding member and above the lower surface portion.

  The present invention relates to a radiopharmaceutical administration device that is advantageous in reducing the external dimensions and saving the space required for installation.

It is a figure for explaining the outline of the embodiment of the present invention. It is a perspective view showing appearance of a radiopharmaceutical administration device of a first embodiment. It is the figure which looked at the partial cross section which cut|disconnected a part of radiopharmaceutical administration apparatus shown in FIG. 2 by xz plane from the front. It is the figure which looked at the partial cross section which cut|disconnected a part of radiopharmaceutical administration apparatus shown in FIG. 2 by yz plane from the left side surface. It is the figure which looked at the partial cross section which cut|disconnected a part of radiopharmaceutical administration apparatus shown in FIG. 1 by yz plane from the right side. It is a front view of a desorption cassette attached to a radiopharmaceutical administration device. It is a rear view of the attachment/detachment cassette shown in FIG. It is a top view of the attachment/detachment cassette shown in FIG. It is a figure which shows the modification of the container holder of 1st embodiment. It is a bottom view of the attachment/detachment cassette of a second embodiment. It is a front view of the attachment/detachment cassette of a second embodiment. It is a rear view of the attachment/detachment cassette of a second embodiment. (A) And (b) is a figure for demonstrating the needle unit of 2nd embodiment.

[Overview]
First, an outline of the present invention will be described prior to specific description of the first and second embodiments of the present invention. In this specification, the first embodiment and the second embodiment are also collectively referred to as the present embodiment. In the description of this outline and the drawings shown in the present embodiment, the same components are designated by the same reference numerals, and the description thereof will be omitted as appropriate. Further, the drawings of the present embodiment are examples of the constituent members of the radiopharmaceutical administration device of the present invention, the arrangement and function of each constituent member, and the positional relationship, and do not limit the specific structure.

  FIG. 1 is a diagram for explaining the outline of the embodiment of the present invention. The radiopharmaceutical administration device 1 of the present embodiment is a radiopharmaceutical administration device for administering a radiopharmaceutical to a living body. The radiopharmaceutical administration device 1 includes a container holding part (corresponding to the container disposing part 12 in FIGS. 3 and 5) that holds a shielded container in which a drug container of the radiopharmaceutical is stored, and the radiopharmaceutical contained in the container holding part. And a plurality of component mounting parts (corresponding to the flow path constituent member disposing part 14 in FIGS. 3 and 4) that constitute a part of the flow path connected to the container. Then, the radiopharmaceutical administration device 1 includes a shielding member 21 that covers at least a part of the container holding portion or the component mounting portion, and a device housing 20 that covers at least a portion of the shielding member 21. The shielding member 21 has a lower surface portion 211b in which a part of the upper surface 211 in the installation direction is lower than the other portion (higher surface portion 211a) of the upper surface 211, and the radiation extracted from the shielding member 21 above the lower surface portion 211b. It has a loose insertion space 50 in which the flow path 31b is loosely inserted.

Of the above, the radiopharmaceutical administration device only needs to have the function of administering the radiopharmaceutical, and may have other functions such as dispensing and synthesis. Here, as for the installation direction, the z direction of the x, y, z coordinates shown in FIG. 1 is “up” and the −z direction is “down” according to the direction of gravity. In the example shown in FIG. 1, the side of the radiopharmaceutical administration device 1 viewed in the y direction is the “front” or “front side” of the radiopharmaceutical administration device 1, and the side of the radiopharmaceutical administration device 1 viewed in the −y direction is “ "Back" or "back".
Since the upper surface 211 has the high surface portion 211a and the low surface portion 211b, the shield member 21 of the radiopharmaceutical administration device 1 has a step. A virtual rectangular parallelepiped having maximum vertical, horizontal, and depth lengths of the shielding member 21 as vertical, horizontal, and depth is overlapped with the actual shielding member 21, and the defective portion of the shielding member 21 with respect to the virtual rectangular parallelepiped is cut out thereafter. Also referred to as a region 210. In the radiopharmaceutical administration device 1, the cutout region 210 is used as the loose insertion space 50.

  The radioactive flow path 31b loosely inserted into the loose insertion space 50 is a flow path through which a liquid containing a radioactive drug flows, and is housed in the device housing 20, preferably in the shielding member 21. The radiopharmaceutical administration device 1 includes a flow channel guiding portion 16 that guides the radioactive flow channel 31b from the opening 211c formed in the lower surface portion 211b to the opening 211d of the device housing 20. The flow path guiding portion 16 is housed in the device housing 20 and can be drawn out from the device housing 20 in the direction of arrow A as necessary. In the radioactive flow path 31b of the radiopharmaceutical administration device 1 as described above, in addition to the length from the opening 211c to the opening 211d, the length that is pulled out together with the flow path guiding unit 16 is required. In order to secure such a margin of length, in this embodiment, the radioactive flow path 31b is loosely inserted in the loose insertion space 50.

In addition, in the present embodiment as described above, it is not necessary to draw the radioactive flow path 31b above the shielding member 21 and draw the radioactive flow path 31b to another portion (for example, the back surface of the radiopharmaceutical administration device). Therefore, when compared with a known radiopharmaceutical administration device that has circulated the radioactive flow channel 31b from the back surface of the radiopharmaceutical administration device 1, the radiopharmaceutical administration device 1 of the present embodiment is used for routing the flow channel. It becomes possible to arrange a comparatively large-sized structure such as a power supply and a control unit in the space. Such a point is further effective for downsizing of the radiopharmaceutical administration device 1.
Furthermore, the configuration in which the radioactive flow path 31b is drawn above the shielding member 21 allows the operator to operate the radioactive flow path 31b while standing on the front surface of the radiopharmaceutical administration device 1. Therefore, the work space around the radiopharmaceutical administration device 1 can be reduced, and the installation area of the radiopharmaceutical administration device 1 can be reduced.

[First embodiment]
(overall structure)
Next, the overall configuration of the radiopharmaceutical administration device 1 according to the first embodiment will be described. Each of FIGS. 2 to 5 is a view showing the radiopharmaceutical administration device 1. Of these, FIG. 2 is a perspective view showing the external appearance of the radiopharmaceutical administration device 1, and FIGS. 3 to 5 are partial cross-sectional views of the radiopharmaceutical administration device 1 viewed from the front, left side, and right side, respectively. In these partial cross-sectional views, cross-sections of the shield region and its peripheral structure are shown, and other configurations are shown in appearance. FIG. 3 is a partial cross-sectional view of a part of the radiopharmaceutical administration device 1 in which the shield door 10 is not attached to the device housing 20, taken along the xz plane. 4 and 5 are partial cross-sectional views of the shielded region of the radiopharmaceutical administration device 1 taken along the yz plane. As shown in FIGS. 2 to 5, in the radiopharmaceutical administration device 1, the vial 7 containing the radiopharmaceutical 27 is placed inside the shielding container 5 together. The radiopharmaceutical administration device 1 extracts the radiopharmaceutical 27 and administers it to the living body.

The radiopharmaceutical 27 is liquid, and its type is not particularly limited. Examples of such radiopharmaceutical 27 include radiopharmaceuticals containing positron emission nuclides (fluorine-18, nitrogen-13, carbon-11, copper-64, etc.) for PET (Positron Emission Tomography) inspection, For example, [ ¹⁸ F]-2-deoxy-2-fluoro-D-glucose), [ ¹⁸ F]flutemethamol, [ ¹⁸ F]florbetapyr, [ ¹⁸ F]florbetaben, [ ¹⁸ F]flucyclobin, [ ¹⁸ F]fluoroethyl. Tyrosine, [ ¹⁸ F]fluoromisonidazole, [ ¹⁸ F]dopamine, [ ¹⁸ F]sodium fluoride, [ ¹¹ C]methionine, [ ¹¹ C]choline derivative, [ ¹¹ C]acetic acid, [ ⁶⁴ Cu]dithiosemi Carbazone derivatives and the like, and radionuclides (technetium-99m, thallium-201, gallium-68, chromium-51, iodine-123) for SPECT (Single Photon Emission Computed Tomography) inspection. , Iodine-125, etc.) or a radiopharmaceutical containing a radionuclide (iodine-131, etc.) for internal radiation therapy.

  The radiopharmaceutical administration device 1 has a configuration for extracting and administering the radiopharmaceutical 27 and a configuration for reducing leakage of radiation to the outside. The shielding member 21 and the device housing 20 are configured to reduce the leakage of radiation to the outside, and of these, the shielding member 21 mainly has a large radiation shielding function. It is sufficient that the shielding member 21 individually covers at least a part of the container disposing portion 12 (container holding portion) or the flow path constituent member disposing portion 14 (constituent mounting portion), and at least one of the container holding portion and the constituent mounting portion. The parts may be covered integrally, but it is preferable that a plurality of shielding regions are provided to individually shield at least a part of the container holding part or the component mounting part. In this embodiment, a case will be described in which the shielding member 21 is provided with two regions (S1, S2) that individually shield at least a part of the container holding portion and the component mounting portion.

The shielding member 21 includes a plurality of shielding walls 21d forming the flow path constituent member arranging portion 14 to a shielding wall 21j, and a shielding door 10a (FIG. 2) that opens or closes the flow path constituent member arranging portion 14 to shield the inside thereof. S2 is formed. As shown in FIG. 4, the shielding door 10 a includes an outer door 100 having an outer surface exposed to the outside of the radiopharmaceutical administration device 1 and an inner door 110 facing the inner surface that is the back surface of the outer door 100. Contains. Here, the term “opposite” means simply facing each other, and the distance between the two does not matter. In the example shown in FIG. 4, the back surface of the outer door 100 and the inner door 110 are in contact with each other.
In addition, the shielding member 21 includes a plurality of shielding walls 21a that form the container disposing unit 12 and a shielding wall 21d that is shared with the flow path forming member disposing unit 14, and a shielding door 10a that opens or closes the flow path forming member disposing unit 14. The shielding area S1 is formed inside by (FIG. 2). Further, the shielding door 10b has a grip portion 11 (FIG. 2), and an operator can hold the grip portion 11 to open or close the shielding door 10b.

  Further, the outer door 100 is formed of an A layer 100a having a high radiation blocking ability and a B layer 100b having a radiation blocking ability lower than that of the A layer. Here, the radiation stopping power refers to a ratio of radiation energy lost per unit length along a path through which charged particles travel in a substance.

As shown in FIGS. 4 and 5, a waste liquid bottle arranging portion 18 for accommodating a waste liquid bottle 180 in which the waste liquid of the radiopharmaceutical 27 is discarded can be opened and closed behind the flow path forming member arranging portion 14 of the device housing 20. A waste liquid bottle storage door 10c for covering is provided. The waste liquid bottle placement unit 18 is a shielded space surrounded by the shield walls 21n, 21o, 21p and the shield wall 21q. The device housing 20 is a metal housing that covers the container placement portion 12, the flow path component placement portion 14, and the waste liquid bottle placement portion 18. However, in the first embodiment, one surface of the flow path forming member disposing portion 14 and the container disposing portion 12 is covered with the shielding doors 10a and 10b, which are shielding members. It covers a part.
On the left side surface of the device housing 20, a flow path housing door 10d that covers the flow path guiding portion 16 is provided. Since the waste liquid bottle storage door 10c and the flow path storage door 10d are provided with the grips 10cc and 10dd, respectively, the operator grips the grips 10cc and 10dd to hold the waste liquid bottle storage door 10c and the flow path. The accommodation door 10d can be opened and closed. In the first embodiment, the flow path housing door 10d is pulled out so as to be movable in the width direction and in the direction away from the housing body.

  Further, as shown in FIG. 2, a power switch 64 for switching on/off of power and an external communication connector 63 for communicating the radiopharmaceutical administration device 1 with the outside are provided on the front surface of the device housing 20. An operation unit 6 is provided in front of the top surface of the housing to allow the operator to instruct the radiopharmaceutical 27 to automatically administer the radiopharmaceutical 27. The information of the living body is displayed. Further, the radiopharmaceutical administration device 1 includes a display 65 such as a touch panel on the upper surface for receiving an input by an operator. An emergency stop switch 62 for stopping the operation of the radiopharmaceutical administration device 1 in an emergency is provided behind the upper surface of the device housing 20, and the radiopharmaceutical 27 is provided in front of the emergency stop switch 62 on the upper surface. There is provided a suspension table 35 on which the saline bag 3 containing the physiological saline solution for pushing out or cleaning the flow path can be suspended.

  Next, the internal structure of the radiopharmaceutical administration device 1 will be described. The radiopharmaceutical administration device 1 according to the first embodiment includes a container holder 122 in a container arranging unit 12 that is a container holding unit that holds the shielded container 5 in which the vial 7 of the radiopharmaceutical 27 is stored. Further, the radiopharmaceutical administration device 1 constitutes a part of the flow path connected to the vial 7 housed in the container holder 122, and at least a part of the plurality of channels has a size different from that of the other part. The structure attachment part to which the flow path component is attached is provided. The component mounting portion of the first embodiment is the flow channel constituent member disposing portion 14, and the flow channel constituent member disposing portion 14 has a saline flow channel 31a, a radioactive flow channel 31b, a first syringe 36a, and a second syringe as the flow channel constituent members. A syringe 36b and three flow path switching members 33a, 33b, 33c are mounted, and an air vented filter 32 is mounted on the radioactive flow path 31b.

  In addition, the radiopharmaceutical administration device 1 includes a shielding member 21 as a configuration for reducing the leakage of radiation to the outside. The shielding member 21 is composed of a plurality of shielding walls 21a to 21k provided so as to individually surround the shielding regions S1 and S2. Further, the container placement part 12 is placed in the shielded region S1, and the flow path constituent member placement part 14 is placed in the shielded region S2.

  Further, the radiopharmaceutical administration device 1 includes the guide passage 160, which is the flow passage guide portion 16 that holds the radioactive flow passage 31b between the opening 211c formed in the shielding member 21 and the opening 211d formed in the device housing 20. I have it. It can be said that such a guide path 160 statically guides the radioactive flow path 31b from the opening 211c to the opening 211d. The flow channel guiding part 16 has a guide channel 160 through which the radioactive flow channel 31b is inserted, a flow channel introducing port 161, and a flow channel outlet 162, and the upper surface (b direction) of the lower surface 211b and the width direction (-x direction). ), and the radioactive flow path 31b loosely inserted into the loose insertion space 50 is drawn in and guided to the outside of the apparatus. Further, the flow channel guiding unit 16 of the first embodiment allows the radioactive flow channel 31b to move in the width direction (−x direction) of the device housing 20. At this time, the radioactive flow path 31b held in the guide path 160 moves in the −x direction together with the guide path 160 and receives tension. In the first embodiment, as described above, the radioactive flow path 31b is bent and loosely inserted in the free insertion space 50 with a margin in its length, which hinders the movement of the flow path guiding portion 16. Therefore, it is possible to prevent the radioactive flow path 31b from falling off the connector 34 or the like.

  Next, the shielding member 21 will be described. As shown in FIG. 3, the radiopharmaceutical administration device 1 forms a shield area S1 by the shield walls 21a, 21b, 21c, 21d, and 21j, and includes a container placement portion 12 in the shield area S1. Further, the shielding wall 21d, 21e, 21f, 21g, 21h, 21i, 21j, 21k forms a shielding region S2, and the flow path forming member arranging portion 14 is provided in the shielding region S2. Further, the radiopharmaceutical administration device 1 has a shielding wall 21m that covers the flow path guiding portion 16 from above. Further, the radiation is also shielded by the shielding walls 21n, 21o, 21p and 21q also in the waste liquid bottle arrangement portion 18 that stores the waste liquid of the radiopharmaceutical 27. The radiopharmaceutical administration device 1 reduces the radiation exposure to the worker by these shield walls 21a to 21q and protects the motors, actuators, and the like constituting each drive mechanism of the present device described later.

  Further, as shown in FIGS. 4 and 5, the radiopharmaceutical administration device 1 includes an uninterruptible power supply (UPS) 70a for supplying electric power to the radiopharmaceutical administration device 1 and driving of each component for administering the radiopharmaceutical. It has electrical equipment such as a control unit 70b and a transformer 70c for controlling the. The control unit 70b includes a small CPU that executes a calculation process for determining the dose of the radiopharmaceutical 27, a memory device, and a driver unit such as a motor or an actuator provided inside the radiopharmaceutical administration device 1. Further, the radiopharmaceutical administration device 1 includes a printer 40, and after administration of the radiopharmaceutical 27, the administration information and the like can be output via the printer 40.

(Container placement section)
Next, the container placement unit 12 will be described. In this embodiment, the container placement unit 12 corresponds to the container holding unit. As shown in FIGS. 3 and 5, in the container placement part 12, a container holder 122 for holding the shielded container 5 for accommodating the vial 7 containing the radiopharmaceutical 27 as a structure for administering the radiopharmaceutical 27, a radioactive substance A needle unit placement portion 124 to which a needle unit 128 for extracting the medicine 27 from the vial 7 is attached is arranged. The needle unit 128 is configured to have a drug extraction needle 125 that extracts a radioactive drug from the vial bottle 7 and a needle holding portion 127 that detachably holds the ventilation needle 126 that is punctured in the vial bottle 7. The container arranging portion 12 is surrounded by shielding walls 21a, 21b, 21c, 21d, and 21j, and the front side of the device housing 20 is openably and closably covered by a shielding door 10b.
The container holder 122 of the container placement part 12 is provided in the device housing 20 and is located below the needle unit placement part 124. Further, the container holder 122 has an inclined surface 123 for holding the shielding container 5 in an inclined manner, and when the medicine extraction needle 125 of the needle unit 128 is inserted into the vial bottle 7 by the inclined surface 123, the inclined vial bottle is inclined. It is possible to descend to the vicinity of the bottom of 7, and the radiopharmaceutical 27 can be extracted in a small amount.

  The needle unit placement portion 124 has a space in which the needle unit 128 can be driven at a position corresponding to a needle guide portion (not shown). The needle unit 128 is mechanically connected to the needle holder 127 (127a, 127b). Further, the needle unit 128, which is one of the flow path constituent members, has a needle drive mechanism 129 that controls the drive amount of the needle holder 127. The needle drive mechanism 129 is composed of a stepping motor or the like, and the drive amount of the needle drive mechanism 129 is transmitted to the mechanically connected needle holding portion 127, and the needle holding portion 127 moves up and down in the needle unit placement portion 124.

(Flow path constituent member)
Next, the flow path forming member will be described. The flow path forming member includes a first needle holding portion 127a and a second needle holding portion 127b (FIG. 5) that detachably hold the needle body that is inserted into the shielding container 5 that contains the radiopharmaceutical 27, and the first needle holding portion. A needle unit 128 having a portion 127a and a second needle holding portion 127b, a radioactive flow path 31b communicating with the shielding container 5 containing the radiopharmaceutical 27 and forming a flow path connected to the radiopharmaceutical 27, and a saline solution. Flowing saline solution flow path 31a, flow path switching members 33a, 33b, 33c provided on the flow path for switching the flow path, a first syringe 36a mainly used for extraction of a radiopharmaceutical, and a physiological saline solution It is composed of a second syringe 36b used for extraction and an air vented filter 32 for removing air on the flow path. In the present specification, when simply referred to as “flow channel”, this flow channel refers to a part of the entire flow channel in which the radiopharmaceutical 27 or the physiological saline flows in the radiopharmaceutical administration device 1.

The above-mentioned flow path forming member can be directly or indirectly attached to the device housing 20. In the first embodiment, an example of indirectly mounting the flow path forming member will be described. In this case, each flow path forming member can be attached to the attachment/detachment cassette 13 which is a substrate that can be attached to the device housing 20, and the attachment/detachment cassette 13 can be installed in the device housing 20 together with the flow path forming member.
6, 7 and 8 are views for explaining the detachable cassette 13. FIG. 6 is a front view of the detachable cassette 13, FIG. 7 is a rear view of the detachable cassette 13, and FIG. It is a top view. As shown in FIGS. 6 to 8, the desorption cassette 13 includes a tube holding portion 132 that holds the saline flow path 31a and the radioactive flow path 31b, and a switching member that holds flow path switching members 33a, 33b, 33c that switch the flow paths. The main substrate 130 includes a holder 135, a syringe holder 136 that holds the first syringe 36a and the second syringe 36b, and a filter holder 138 that holds the air vented filter 32. According to such a detachable cassette 13, the saline flow path 31a, the radioactive flow path 31b, the flow path switching members 33a, 33b, 33c, the first syringe 36a, the second syringe 36b, and the air vented filter 32 are held. By mounting on the device housing 20 of the radiopharmaceutical administration device 1, the saline flow path 31a, the radioactive flow path 31b, the flow path switching members 33a, 33b, 33c, the first syringe 36a, the second syringe 36b, and the air vented filter. A disposable member such as 32 can be easily set. Further, after the administration of the radiopharmaceutical 27, these disposable members together with the detachable cassette 13 can be easily removed from the device housing 20.

  Further, the main board 130 has a mounting hole 19 and a handle portion 17 for mounting on the flow path component disposing portion 14. A flow path component holding portion 144 (for example, a convex portion) is provided at a position corresponding to the mounting hole 19 of the flow path constituent member placement portion 14, and the mounting hole 19 and the flow path constituent member holding portion 144 are engaged with each other. Thus, the main substrate 130 can be mounted on the flow path component disposing portion 14. However, this mounting method is an example, and if the main substrate 130 can be mounted on the flow channel component disposing portion 14, the structure on the main substrate 130 side and the flow channel component holding portion 144 are particularly Not limited.

A plurality of tube holding portions 132 may be provided, which can hold the saline flow channel 31a and the radioactive flow channel 31b, and the saline flow channel 31a so as not to interfere with other components provided on the main substrate 130. As long as the radioactive flow path 31b can be routed, the number and shape are not particularly limited. For example, in FIG. 6, eight tube holding portions 132 are provided.
In the first embodiment, the main substrate 130 has, for example, three switching member holding portions 135 arranged adjacent to each other in the width direction and below the syringe holding portion 136. The switching member holding portion 135 is formed in a circular disk shape when viewed from the front, is provided on the main substrate 130 in a state of penetrating the main substrate 130, and is rotatable relative to the main substrate 130. It is held by the main substrate 130.

  The syringe holding part 136 of the first embodiment is composed of two parts, a first syringe holding part 136a and a second syringe holding part 136b, and the two syringe holding parts are arranged on the same plane and adjacent to each other on the left and right. In FIG. 6, the first syringe holder 136a is arranged on the left side of the second syringe holder 136b. The filter holder 138 has a shape capable of holding the air vented filter 32 and is not particularly limited in shape and position as long as it does not interfere with other components, but the detachable cassette 13 is attached to the apparatus housing 20. In this case, it is preferable to be located below the cutout region 210.

  Further, the detachable cassette 13 further includes a sub-board 131 having two needle holding portions 127, a first needle holding portion 127a and a second needle holding portion 127b, and a needle guide portion 133 to which each needle holding portion can move. The sub-board 131 is fixed to the main board 130. The main board 130 and the sub-board 131 are each formed in a disk shape, and are arranged vertically. The main board 130 and the sub-board 131 are connected to each other at right angles by a connecting member 139 and are provided in parallel with each other. That is, the plane on which the main substrate 130 is arranged and the plane on which the sub substrate 131 is arranged are provided in parallel to each other on different planes. According to the detachable cassette 13 including the main substrate 130 and the sub-substrate 131, it is not necessary to directly provide the needle holding portion 127 or the needle guide portion 133 on the device housing 20 of the radiopharmaceutical administration device 1, and the needle is a disposable member. The body can be easily set and removed.

For example, the medicine extraction needle 125 can be attached to the first needle holding portion 127a, and the ventilation needle 126 can be attached to the second needle holding portion 127b. The first needle holder 127a and the second needle holder 127b are movable along linear guide holes 134a and 134b formed in the sub-board 131. That is, the first needle holding portion 127a is movable along the guide hole 134a, and the second needle holding portion 127b is movable along the guide hole 134b. In the first embodiment, the guide hole 134a and the guide hole 134b are arranged adjacent to each other, the guide hole 134a extends in the vertical direction, and the guide hole 134b is inclined downward in a direction approaching the guide hole 134a. ing.
The detachable cassette 13 is not limited to such a configuration, and is a convex portion or a concave portion that can be fitted to the flow channel component holding portion 144 of the flow channel component placement portion 14 and can be mounted on the device housing 20. Any substrate may be used. Such a substrate is preferably a substrate that can be attached to and detached from the apparatus housing 20, like the detachable cassette 13. In addition, in the first embodiment, the detachable cassette 13 to which the flow path forming member is attached is one of the flow path forming members.

(Flow path component placement part)
Next, the flow path constituent member disposing portion 14 will be described. In the first embodiment, the flow path constituent member disposing portion 14 corresponds to the constituent mounting portion. Further, in the first embodiment, an example will be described in which the flow path forming member is attached to the flow path forming member placement portion 14 via the above-described detachable cassette 13. However, the first embodiment is not limited to the configuration in which the flow path forming member is attached to the flow path forming member disposing portion 14 via the detachable cassette 13, and the flow path forming member is directly attached to the radiopharmaceutical administration device 1. Good. In such a case, members (tube holding portion 132, switching member holding portion) excluding the mounting hole 19 and the handle portion 17 of the main substrate 130 shown in FIG. 6 are provided on the front surface of the flow path constituent member placement portion 14 of the radiopharmaceutical administration device 1. A substrate (not shown) on which the 135, the first syringe holding portion 136a, and the second syringe holding portion 136b) are formed is integrally formed with the flow path constituent member arranging portion 14, and this substrate functions as a component mounting portion.

  The radiopharmaceutical administration device 1 of the first embodiment extracts the radiopharmaceutical 27 from the vial 7 in the shielding container 5 through the flow path 31d forming the flow path of the radiopharmaceutical 27, and administers the extracted radiopharmaceutical 27. And a plurality of syringe drive parts 142 for driving the plunger parts 37a, 37b of the first syringe 36a and the second syringe 36b, and a flow path component holding part for fitting with the detachable cassette 13 in which the flow path component is mounted. 144, and a flow path switching member holding portion 146 that is provided on the flow path and holds the flow path switching members 33a, 33b, and 33c that switch the flow paths. The syringe drive unit 142 is located above the flow path constituent member disposing unit 14 and is provided above the flow path switching member holding unit 146. The flow path switching member holding unit 146 is the flow path constituent member disposing unit. The flow path component holding portion 144 is located in the lower part of the flow path 14, and is located substantially at the center of the flow path component placement part 14. Here, the approximate center is lower in the vertical direction than the syringe drive section 142 and higher than the flow path switching member holding section 146, and is not particularly limited. Further, the flow path component holding portion 144 of the first embodiment has a concave shape (recess). However, the flow path component holding portion 144 may be, for example, a convex portion provided with a concave portion on the side of the radiopharmaceutical administration device 1 and used as the concave portion. Further, the flow path component holding portion 144 is not limited to a configuration that fits with the radiopharmaceutical administration device 1, and any component may be used as long as it is engaged with the radiopharmaceutical administration device 1 so that the detachable cassette 13 is fixed. It may be one.

  The syringe drive unit 142 is provided in the device housing 20 and can move up and down by using the motor 300 as a drive source, as shown in FIG. The syringe drive part 142 is a plunger fitting part that fits with the plunger part 37a of the first syringe 36a and the plunger part 37b of the second syringe 36b, which are part of the flow path forming member, and that fits with the respective plunger parts. 143a and 143b are provided, and the plunger fitting portions 143a and 143b have a shape provided with an engagement groove that is opened on the front side of the apparatus (-y direction in FIG. 2). Therefore, the plunger portions 37a and 37b of the respective syringes are held by fitting the first syringe 36a and the second syringe 36b into the plunger fitting portions 143a and 143b from the front side of the device.

  Further, the motor 300, which is a drive source, vertically moves the plunger fitting portions 143a and 143b, and vertically moves the held plunger portions 37a and 37b individually. Here, the motor 300 is preferably a stepping motor or the like that is driven with high accuracy according to a control signal. Further, the flow line of the syringe drive section 142 is not particularly limited as long as it does not interfere with other constituent members when the plunger fitting sections 143a and 143b move up and down, but in FIG. 3, the plunger engagement sections 143a and 143b are shown. Have openings 147a and 147b extending in the moving direction (vertical direction or z direction). The openings 147a and 147b function as guide holes when the plunger fitting portions 143a and 143b move up and down. Further, in the first embodiment, the motor 300 is shown as the power source of the syringe drive unit 142, but the drive source is not particularly limited, and an actuator such as a cylinder may be used as the drive source.

  The flow path forming member holding portion 144 is not particularly limited as long as it is provided in the device housing 20 and can hold the flow path forming member that forms the flow path used for administration of the radiopharmaceutical 27. The flow path component holding portion 144 has a convex portion that fits into the mounting hole 19 provided in the detachable cassette 13, and indirectly mounts and holds the flow path component member on the device housing 20.

  The flow path switching member holding portion 146 is a plurality of flow path switching member holding portions that are provided in the device housing 20 and hold the flow path switching members 33a, 33b, and 33c that are a part of the flow path constituent members. The flow path switching members 33a, 33b, 33c are typically three-way stopcocks, and also three-way stopcocks in the first embodiment. In the first embodiment, the flow path switching member holding portions 146 are provided, for example, three corresponding to the flow path switching members 33a, 33b, and 33c, and one of these is provided in the plunger fitting portion 143a of the first syringe. The other one is arranged below the plunger fitting portion 143b of the second syringe, and the other one is arranged in parallel in the horizontal direction. The flow path switching member holding portion 146 has engagement grooves opened to the front side of the apparatus (-y direction), and the flow path switching members 33a, 33b, 33c are engaged with these engagement grooves from the front side. Let it hold. Each flow path switching member holding portion may be formed in a disc shape when viewed from the front of the present device, and is rotatably provided independently of the device housing 20, as shown in FIG. 4, for example. Mechanically connected to such a motor 310, the flow path switching members 33a, 33b, 33c are rotated according to the rotation of the motor 310 to switch the flow path.

(Flow path guide part)
Next, the flow channel guiding unit 16 will be described. As shown in FIG. 4 and FIG. 5, in the first embodiment, the flow channel guiding unit 16 uses the saline flow channel 31a and the radioactive flow channel 31b, which are led out through the shielding wall 21g forming the shielding region S2, as a device. Takes the role of guiding to the outside. The flow path guiding portion 16 is provided at a position higher than the shielding region in the vertical direction and higher than the loose insertion space 50. Further, the flow path guiding portion 16 is located away from the center line L in the width direction of the loose insertion space 50 in the width direction of the device housing 20 and in the direction away from the center line L.

As shown in FIG. 4, the flow path guiding unit 16 has a guide path 160 that accommodates the flow path led out from the shielding wall 21g. The guide path 160 has a flow path inlet 161 for introducing a flow path at one end and a flow path outlet 162 for guiding a flow path at the other end. In the first embodiment, the flow path inlet 161 is provided at a position lower than the flow path outlet 162, and the guide path 160 is inclined toward the front surface of the apparatus. The flow channel inlet 161 is provided near the upper portion of the cutout region 210, and the flow channel outlet 162 is provided near the center of the upper side surface of the apparatus housing 20 in the depth direction.
The saline flow path 31a and the radioactive flow path 31b led out from the shielding wall 21g are loosely inserted in the loose insertion space 50 in a bent state. The saline flow path 31a is led out to the outside from the side surface of the device as it is, and the radioactive flow path 31b is introduced into the flow path introducing port 161 by the flow path guiding unit 16 and then continues through the guide path 160 to the flow path guiding port 162. Is guided to the outside of the device. A shield wall 21m is preferably provided above the guide path 160 in order to reduce radiation exposure to an operator standing in front of the apparatus when the radiopharmaceutical 27 passes through the guide path 160. is there.

  Further, in the first embodiment, the flow path guiding unit 16 is movable in the width direction and the direction away from the device housing 20 (left direction in FIG. 3, front direction in FIG. 4) by using a rail (not shown). Be withdrawn. It is preferable that the guide path 160 is formed in a concave shape and that the flow path to be fitted can be visually recognized from the upper side in a state where the flow path guide portion 16 is pulled out. The concave shape is not particularly limited, but may be a U-shaped shape, a V-shaped shape or the like that can accommodate the flow path.

Here, the effect of the flow channel guiding unit 16 of the first embodiment will be described. The first embodiment contributes to the reduction of the external dimensions of the entire apparatus by movably drawing out the flow path guiding unit 16. The flow passage outlet 162 is provided on the upper portion of the side surface of the device rather than on the back side of the device, and the flow passage guiding portion 16 draws the flow passage toward the flow passage outlet 162, so that the flow passage is moved forward and backward inside the device. It is not necessary to provide a crossing space, and the electrical structure (for example, uninterruptible power supply (UPS) 70a, control unit 70b, etc.) included in the radiopharmaceutical administration device 1 is arranged in the newly created space. Because you can. This makes it possible to reduce the outer dimension of the entire radiopharmaceutical administration device in the vertical direction.
In addition, the first embodiment contributes to improving the operability of the operator by movably drawing out the flow path guiding unit 16. That is, when setting the flow channel constituent member in the radiopharmaceutical administration device 1 to administer the radiopharmaceutical 27 to the living body, the flow channel guiding part 16 is pulled out to the side face of the device without the operator moving from the front face of the device. Thus, the flow path can be stored around the guide path 160 having a concave shape and can be routed. Further, by forming the guide path 160 into a concave shape, the accommodated flow path can be visually recognized, and setting of the flow path constituent member can be facilitated. Further, in the first embodiment, an example in which the guide path 160 stores only the radioactive flow path 31b has been described, but the saline flow path 31a and the radioactive flow path 31b may be stored together.

(Shielding member)
Next, the shielding member 21 will be described with reference to FIGS. 3 to 5. In the first embodiment, the radiopharmaceutical administration device 1 has a shielding member 21 as a configuration for reducing leakage of radiation to the outside. The shielding member 21 covers at least a part of the container disposing portion 12 (shielding region S1) and the flow path forming member disposing portion 14 (shielding region S2), and has shielding walls 21a to 21m as outer walls thereof. Note that one side surface of the shielding member 21 on the front side of the device is shielding doors 10a and 10b that individually open or close the container disposing portion 12 and the flow path component disposing portion 14. Here, the material of the shielding walls 21a to 21k and the shielding doors 10a and 10b is not particularly limited as long as it has a radiation blocking ability capable of shielding radiation (eg, gamma rays, X-rays, etc.), but is preferably aluminum. Metals such as lead and tungsten, aluminum and tungsten are preferable from the viewpoint of weight per unit volume, and aluminum and lead are preferable from the viewpoint of ease of processing. Further, each shield wall or shield door may be formed of a single material, or may be formed of two or more kinds of materials having different radiation blocking ability.

  The shielding region S1 formed by the shielding member 21 covering at least a part of the container placement portion 12 will be described with reference to FIGS. 3, 4, and 5. In addition to the shielding door 10b not shown in FIG. 3, the container disposing portion 12 is close to the upper surface side of the needle unit disposing portion 124 and the shielding wall 21a that covers the shielding area S1, and the right side surface of the needle unit disposing portion 124. And a shielding wall 21b that covers the shielding region S1, a shielding wall 21c that covers the shielding region S1 near the rear side of the needle unit placement portion 124 and the container holder 122, and a shielding wall 21d that covers the left side surface of the needle unit placement portion 124. It is formed by and. Below the shielding wall 21d, there is an opening (not shown) for mounting the attachment/detachment cassette 13 in which the flow path forming member is mounted. Further, the shielding wall 21b has an opening 24 below it. This is because the leakage of radiation toward the side surface of the shielding container 5 is sufficiently reduced by the shielding container 5 itself. Further, for the same reason, there is no shielding wall below the container placement portion 12 (-z direction in FIG. 3). By appropriately providing an opening or the like in consideration of the radiation blocking ability of each wall surface, the total volume of the shielded region S1 can be reduced, and the external dimensions of the radiopharmaceutical administration device 1 as a whole can be reduced.

  Next, the shielding member 21 that covers the flow path forming member arrangement portion 14 will be described. In addition to the front-side shield door 10a not shown in FIG. 3, the flow path component disposing portion 14 includes a shield wall 21d that is close to the right side surface of the syringe drive portion 142 and covers the shield area S2, and the syringe drive portion 142. The shielding wall 21e which is close to the side surface and covers the shielding area S2, the shielding wall 21f which is close to the left side surface of the syringe driving unit 142 and covers the shielding area S2, and the lower left side surface of the flow path component holding portion 144 are A hole that connects the shielding wall 21h close to the left side surface of the vented filter 32 and covers the shielding region S2, the shielding wall 21f and the shielding wall 21h, and penetrates the saline flow path 31a and the radioactive flow path 31b (FIG. 1). (Corresponding to the opening 211c) of the flow path switching member holding portion 146, a shield wall 21i close to the right side surface of the flow path switching member holding portion 146, and a bottom surface of the flow path constituent member disposing portion 14. And a shielding wall 21j that covers the shielding region S2 and a shielding wall 21k that covers the shielding region S2 in close proximity to the back surface side of the flow path component disposing portion 14. Further, the shield wall 21c that covers the back surface side of the container placement portion 12 and the shield wall 21k that covers the back surface side of the flow path component placement portion 14 are provided in parallel to each other, but are mounted on the radiopharmaceutical administration device 1. They are provided on different planes that are separated in the front-rear direction by a distance corresponding to the length of the connecting member 139 of the detachable cassette 13 in the depth direction.

  The shielding door 10a that opens or closes the flow path component disposing portion 14 may be a single one, but as shown in FIG. 4, it is preferable that the shielding door 10a is composed of a plurality of outer doors 100 and inner doors 110. is there. In the first embodiment, the shielding door 10a is a plurality of shielding doors including the outer door 100 and the inner door 110, and is provided so as to overlap each other. The material of each shielding door is a shielding member having a radiation blocking ability. In the first embodiment, the inner door 110 is made of a single material having a high radiation blocking ability, and the outer door 100 has an A layer 100a having a high radiation blocking ability and a B layer having a lower radiation blocking ability than the A layer. It is made of two kinds of materials 100b. The inner door 110 and the A layer 100a of the outer door 100 are preferably made of the same material.

  Next, the positional relationship between the outer shielding door 100 and the inner shielding door 110 that covers the flow path component disposing portion 14 will be described. As shown in FIG. 4, the inner shielding door 110 covers the flow path constituent member holding portion 144 (FIGS. 3 and 7) and the flow path switching member holding portion 146 (FIG. 3) of the flow path constituent member placement portion 14, and The outer door 100 is provided so as to overlap the outer side (rightward in FIG. 4 ), and the outer door 100 covers the syringe drive unit 142 and the inner door 110. More specifically, the A layer 100a of the outer door 100 covers the syringe drive section 142, and the B layer 100b covers the syringe drive section 142 and the inner door 110. Further, the outer door 100 (a part of the A layer and the B layer) and the upper ends of the inner door 110 are provided with steps so as to engage with each other.

  The radiation blocking ability of the inner door 110 is formed to be higher than the radiation blocking ability of the outer door 100 (A layer 100a and B layer 100b). When these shielding doors are arranged in the order of high radiation blocking ability, the inner door 110, the outer layer A layer 100a, and the B layer 100b are in order. This is based on the fact that the radiopharmaceutical 27 passes from the vial 7 through the flow path 31d and on the radioactive flow path 31b of the detachable cassette 13 fitted into the flow path component holding portion 144. In the syringe drive unit 142 in which the radiopharmaceutical 27 does not pass in the vicinity, and in the flow path constituent member holding unit 144 and the flow path switching member holding unit 146 in which the radiopharmaceutical 27 passes in the vicinity, the flow path constituent member holding unit 144 and the flow path switching are performed. The amount of radioactivity of the member holding portion 146 is higher. That is, the outer door 100 is formed such that the region with a high radiation dose is covered with the inner door 110 formed to have a high radiation blocking ability, and the region with a low radiation dose is formed to have a lower radiation blocking ability than the inner door 110. By covering with, the total volume of the shielded region S2 can be reduced, and the overall external dimensions of the radiopharmaceutical administration device 1 can be reduced.

(Free insertion space (notched area))
Next, the cutout area 210 and the loose insertion space 50 generated by the cutout area 210 will be described. The cutout area 210 is composed of the shielding walls 21f and 21g. The cutout region 210 is not formed by “cutting out” a part of the shield member 21, but if the shield member 21 is conceptually in the shape of a rectangular parallelepiped, the shield member 21 will be partially cut out. Since the shape is defective, the portion corresponding to the defective portion is called a cutout region. The cutout region 210 is designed so that the shielding wall 21g is lower than the shielding wall 21e, and the shielding wall 21e is the high surface portion 211a and the shielding wall 21f is the low surface portion 211b shown in FIG. Since the cutout region 210 is not a member having a substance but a space, the loose insertion space 50 is formed overlapping with the cutout region 210. The loose insertion space 50 is a space into which the radioactive flow passage 31b having a length in consideration of being drawn out together with the flow passage guiding portion 16 is gently inserted (i.e., loosely inserted) in a bent state.

  In addition, the above-mentioned configuration has the flow path forming members (the first syringe 36a, the second syringe 36b, the air vented filter 32, the saline flow path 31a, the radioactive flow path 31b and the flow path) arranged in the flow path forming member arrangement portion 14. This is because the size of the path switching members 33a, 33b, 33c) and the range of installation are different. That is, in the flow path component disposing portion 14, it is necessary to secure a height where the plunger fitting portions 143a and 143b move up and down in the region where the syringe driving portion 142 is located. On the other hand, it is not necessary to secure a height in which the air vented filter 32 is located so as to move up and down. The inventors of the present invention pay attention to such a point, and do not adjust the shielding member 21 according to the size of each flow path forming member, rather than adjusting the shielding member 21 to a large space for arrangement. Space is excluded. Then, by making the removed space outside the shielding member 21, the exclusive volume of the shielding region S2 can be reduced. Then, in the first embodiment, the generated loose insertion space 50 is utilized to route the radioactive flow passage 31b, and another configuration that is electrically used in the space that has been used to route the flow passage (uninterruptible power supply device) is used. By accommodating (UPS) 70a, etc., the external dimensions of the radiopharmaceutical administration device 1 can be reduced.

(motion)
Next, the operation of the radiopharmaceutical administration device 1 having the above-described configuration during administration will be described. In the description of this operation, the shielding container 5 is placed on the container holder 122, and the flow path components (first syringe 36a, second syringe 36b, air vented filter 32, saline flow path 31a, radioactive flow path 31b). And the flow path switching members 33a, 33b, 33c) are attached to the detachable cassette 13 to the flow path constituent member disposing portion 14, and the second syringe 36b is filled with a fixed amount of the physiological saline solution sucked from the saline bag 3. It is assumed to be stored. Further, in the first embodiment, the operator touches a display such as “start of administration” displayed on the display 65, so that the control unit 70b detects the contact pressure on the display 65, and the preset administration program ( Hereinafter, a case will be described in which the program is simply started and started, but the means for notifying the control unit 70b of the start of administration is not limited to this.

  The control unit 70b activates the program and first operates the needle driving mechanism 129 to move down the first needle holding unit 127a having the medicine extraction needle 125 attached thereto and the second needle holding unit 127b having the ventilation needle 126 attached thereto. The needle tip of the drug extraction needle 125 is lowered to near the bottom of the inclined vial 7 through the stopper of the vial 7. At this time, the flow path switching member 33b makes the first syringe 36a and the flow path 31d communicate with each other, the first syringe 36a and the vial bottle 7 communicate with each other through the flow path 31d, and the vial needle 126 allows the vial bottle. The inside of 7 is kept at normal pressure.

  Next, the control unit 70b rotates the motor 300 by a preset number of rotations according to the program to raise the plunger 37a of the first syringe 36a. As a result, the radiopharmaceutical 27 in an amount corresponding to the rotation speed of the motor is sucked from the vial 7 into the first syringe 36a through the drug extraction needle 125, the flow path 31d, the flow path switching member 33a, and the flow path switching member 33b.

  Next, the control unit 70b operates the needle drive mechanism 129 according to the program to raise the drug extraction needle 125 to a position where it is sufficiently separated from the liquid surface of the radiopharmaceutical 27 in the vial 7. After that, the motor 300 is further rotated to raise the plunger 37a of the first syringe 36a to supply a predetermined amount of air to the ventilation needle 126, the vial 7, the drug extraction needle 125, the flow passage 31d, the flow passage switching member 33a, Suction into the first syringe 36a through the flow path switching member 33b. As a result, the amount of radiopharmaceutical remaining in the drug extraction needle 125, the flow channel 31d, the flow channel switching member 33a, and the flow channel switching member 33b is reduced, and a desired amount of the radiopharmaceutical 27 can be sucked.

  Next, according to the program, the control unit 70b rotates the motor 310 to rotate the flow path switching member 33b to connect the first syringe 36a to the radioactive flow path 31b, the total amount flow path 31c, and the air vented filter 32. Subsequently, the control unit 70b rotates the motor 300 to lower the plunger portion 37a of the first syringe 36a to deliver the total amount of the radiopharmaceutical 27 stored in the first syringe 36a to the total amount flow path 31c. As a result, the total amount of the radiopharmaceutical 27 advances in the flow path 31c and passes through the air vented filter 32. At this time, the air sucked into the first syringe 36a is removed by the air vented filter 32. The radiopharmaceutical 27 that has passed through the air vented filter 32 is administered to the living body through the radioactive flow path 31b.

  Next, the control unit 70b rotates the motor 310 in accordance with the program to connect the flow path switching members 33a and 33b to each other. Further, the motor 310 is rotated to connect the flow path switching member 33a and the second syringe 36b. As a result, the first syringe 36a and the second syringe 36b communicate with each other via the flow path switching member 33a and the flow path switching member 33b. Next, the motor 300 is rotated by a preset number of rotations to raise the plunger portion 37a of the first syringe 36a and draw the physiological saline solution stored in the second syringe 36b into the first syringe 36a. At this time, the motor 300 that drives the plunger portion 37b of the second syringe 36b is reversely rotated by the same amount as the operation amount of the motor that drives the plunger portion 37a of the first syringe 36a, and the plunger portion 37b of the second syringe 36b is lowered. Let

  Next, the control unit 70b rotates the motor 310 according to the program to rotate the flow path switching member 33b to connect the total amount flow path 31c and the first syringe 36a. Then, the motor 300 is rotated by a preset number of rotations to lower the plunger 37a of the first syringe 36a, and the physiological saline solution stored in the first syringe 36a is delivered to the entire flow path 31c. The delivered physiological saline solution is administered to the living body through the total flow path 31c, the air vented filter 32, and the radioactive flow path 31b. As a result, the inside of the first syringe 36a, the total amount flow path 31c, the air vented filter 32, and the radioactive flow path 31b can be washed with physiological saline, and as much radiopharmaceutical remaining on the flow path as possible can be administered to the living body. Is possible. With the above operation, administration of the radiopharmaceutical 27 to the living body is completed.

  The operation of the first embodiment is not limited to the above. For example, the radiopharmaceutical 27 is completely sucked from the vial 7 into the first syringe 36a, a predetermined amount is administered, and then the motor is rotated. Then, the waste flow path (not shown) may be communicated with the first syringe 36a, and the rest may be sent to the waste flow path. In this case, the radiopharmaceutical 27 that has not been administered to the living body progresses through the waste flow path and is stored in the waste liquid bottle 180.

  Further, in the first embodiment, an example in which the flow path forming member is indirectly attached to the radiopharmaceutical administration device 1 via the desorption cassette 13 has been shown, but the present invention is not limited to such a configuration. Alternatively, the flow path forming member may be directly attached to the radiopharmaceutical administration device. In that case, each holding portion included in the detachable cassette 13 may be configured to be included in the flow path component disposing portion 14 of the apparatus body.

[Modification]
Further, in the first embodiment, an example in which the container holder 122 is provided in the device housing 20 has been described, but the present invention is not limited to such a configuration.
FIG. 9: is a figure which shows the modification of the container holder of 1st embodiment. In the first embodiment, as shown in FIG. 9, the container holder may be a container holder 222 provided on the inner door 110 that constitutes the shielding door 10b of the shielding door 10. With such a configuration, the first embodiment can be expected to improve the operability of the operator by reducing the transportation distance of the shielding container 5 which is generally a heavy object.

[Second embodiment]
Next, a second embodiment of the present invention will be described. The radiopharmaceutical administration device 1 of the second embodiment is the same as that of the first embodiment except the configuration of the needle unit. Therefore, in the second embodiment, part of the illustration and description of the configuration other than the detachable cassette and the needle unit are omitted.
As in the first embodiment, the flow path forming member of the second embodiment is indirectly attached to the radiopharmaceutical administration device 1 via the detachable cassette 43. 10 is a bottom view of the attachment/detachment cassette 43, FIG. 11 is a front view of the attachment/detachment cassette 43 in which a flow path forming member is attached, and FIG. 12 is a rear view. Here, as shown in FIG. 10, in the second embodiment, the main substrate 430 and the sub-substrate 431 of the attachment/detachment cassette 43 are connected by an L-shaped connecting member 439. That is, the first needle holding portion (not shown) and the second needle holding portion (not shown) provided on the sub-board 431 of the detachable cassette 43 are aligned in the normal direction to the main board 430 (the front-back direction when mounted on the device). It is located at. As a result, the widthwise dimension of the desorption cassette 43 can be shortened, the widthwise dimension of the shielding region S2 of the device housing in which the desorption cassette 43 is mounted can be shortened, and the outer dimension of the radiopharmaceutical administration device in the widthwise direction can be reduced. Can be made smaller.
Further, in this case, it is preferable that the slope 123 of the container holder 122 of the container disposing unit 12 is provided in the same direction as the needle holding units are arranged.

  13A and 13B are views for explaining the needle unit 228 of the second embodiment. The needle unit 228 holds the first needle holding portion 127a, which is the extraction needle holding portion, and the second needle holding portion 127b, which is the ventilation needle holding portion, so that they are arranged in the front-rear direction intersecting the width direction of the device housing. It is provided with guide holes 434a and 434b which are needle guides for moving up and down. Here, the front-back direction is a direction intersecting the x, y planes shown in FIGS. 1 to 5, and preferably the y direction or substantially the y direction. The first needle holding portion 127a is configured to hold the drug extraction needle 125, and the second needle holding portion 127b is configured to hold the ventilation needle 126. FIG. 13A shows a state before the medicine extraction needle 125 and the ventilation needle 126 are lowered, and FIG. 13B shows a state where the medicine extraction needle 125 and the ventilation needle 126 are lowered.

  As shown in FIGS. 13A and 13B, in the needle unit 228, the first needle holding portion 127a and the second needle holding portion 127b are arranged in a direction intersecting the width direction of the device housing 20. It has a needle guide part that moves up and down while holding it. The needle guide portion of the second embodiment is a first guide groove (guide hole) 434a and a second guide groove (guide hole) 434b extending in the vertical direction. In the second embodiment, the guide hole 434b is formed so as to bend near the center in a direction approaching the guide hole 434a. However, in the second embodiment, conversely, the guide hole 434b may be formed so as to bend in a direction approaching the guide hole 434a. With such a configuration, in the second embodiment, the needle unit 228 can be attached so as to extend in the depth direction of the radiopharmaceutical administration device 1, so that the needle unit 228 occupies the width direction of the radiopharmaceutical administration device 1. The mounting space can be reduced.

Further, the drug extraction needle 125 and the ventilation needle 126 are in a state of being covered with a cap until immediately before the attachment to the radioactive drug administration device 1. In the known radiopharmaceutical administration device, the cap cannot be attached to the drug extraction needle 125 and the ventilation needle 126 covered with the cap, so that the cap cannot be attached in the state shown in FIG. It had to be attached to the drug administration device 1. For this reason, in the known radiopharmaceutical administration device 1, it has been necessary to take care so that the needles do not get stuck in the fingers of the worker when the drug extraction needle 125 and the ventilation needle 126 are attached.
On the other hand, in the needle unit 228 of the second embodiment, as shown in FIG. 13A, the drug extraction needle 125 and the ventilating needle 126 can be attached so as to be sufficiently separated from each other. Both can be attached to the radiopharmaceutical administration device 1 while the cap 126 is covered. Such a second embodiment can reduce the risk of a needle stick of an operator when attaching the drug extraction needle 125 and the ventilating needle 126 to the attachment/detachment cassette 43 or attaching the attachment/detachment cassette 43 to the device housing 20.

The above embodiments include the following technical ideas.
(1) A radiopharmaceutical administration device for administering a radiopharmaceutical to a living body, comprising: a container holding part that holds a shielding container in which a drug container of the radiopharmaceutical is contained; and the container contained in the container holding part. A component mounting portion to which a plurality of flow channel constituent members constituting a part of the flow channel connected to the drug container are mounted, and at least a part of the container holding part or the component mounting part is covered and released from the radiopharmaceutical. And a device housing that covers at least a part of the shielding member, wherein the shielding member has a lower surface part in which a part of the upper surface in the installation direction is lower than other parts of the upper surface. A radiopharmaceutical administration device having a loose insertion space, which is provided above the lower surface portion and in which the flow path drawn out from the shielding member is loosely inserted.
(2) The radiopharmaceutical administration device according to (1), wherein the shielding member is provided with a plurality of shielding regions that individually shield the container holding portion and the component mounting portion.
(3) The method according to (1) or (2), further including a flow channel guiding portion that holds the flow channel between a first opening formed in the shielding member and a second opening formed in the device housing. Radiopharmaceutical administration device.
(4) The radiopharmaceutical administration device according to (3), wherein the flow channel guiding unit makes the flow channel movable in the width direction of the device housing.
(5) The radiopharmaceutical administration device according to any one of (1) to (4), wherein a part of the flow path is routed upward in the loose insertion space and in the width direction of the device housing.
(6) The shielding member has a plurality of shielding walls that form a shielding space and a shielding door that opens or closes the shielding space, and the shielding door has an outer surface exposed to the outside of the radiopharmaceutical administration device. The radiopharmaceutical administration device according to any one of (1) to (5), including an outer door and an inner door that faces an inner surface that is a back surface of the outer door with respect to the outer surface.
(7) One or a plurality of syringe drive units that drive the plunger section of the syringe to extract the radiopharmaceutical from the shielded container through the flow channel, and the configuration mounting section are provided on the flow channel. A flow path switching member holding portion holding a flow path switching member for switching the flow paths is attached, the inner door covers the flow path switching member holding portion, and the outer door is the syringe drive portion and the inner door. The radiopharmaceutical administration device according to (6), which covers the.
(8) The radiopharmaceutical administration device according to (6) or (7), wherein the radiation blocking ability of the inner door is higher than the radiation blocking ability of the outer door.
(9) The radiopharmaceutical administration device according to any one of (6) to (8), wherein the container holding portion is provided on the inner door of the shielding door.
(10) A needle unit that detachably holds an extraction needle holding part that holds an extraction needle that extracts the radiopharmaceutical from the drug container, and a ventilation needle holding part that holds a ventilation needle punctured in the drug container. Further, the needle unit has a needle guide portion that moves up and down while holding the extraction needle holding portion and the ventilating needle holding portion so as to be arranged in a front-back direction intersecting the width direction of the device housing, The radiopharmaceutical administration device according to any one of (1) to (9).
(11) The needle guide portion is a guide groove extending in the vertical direction, and a first guide groove in which one of the extraction needle holding portion and the ventilation needle holding portion moves and a second in which the other moves. And the guide groove, and one of the first guide groove and the second guide groove is bent in a direction approaching the other, (10).

DESCRIPTION OF SYMBOLS 1... Radiopharmaceutical administration device 3... Saline bag 5... Shielding container 6... Operation part 7... Vial bottle 10, 10a, 10b... Shielding door 10c... Waste liquid bottle accommodation door 10d... Flow path storage doors 10cc, 10dd, 11... Gripping section 12... Container placement section 13, 43... Desorption cassette 14... Flow path component placement section 16... Flow path guidance Part 17... Handle part 18... Waste liquid bottle placement part 19... Mounting hole 20... Device housing 21... Shielding members 21a-21q... Shielding wall 24... Opening 27... Radiopharmaceutical 31a... Saline flow path 31b... Radioactive flow path 31c... Total quantity flow paths 33a, 33b, 33c... Flow path switching member 31d... Flow path 32... Air vented filter 34... Connector 35... Suspension stand 36a... First syringe 36b... Second syringe 37a, 37b... Plunger section 40... Printer 50... Free insertion space 62... Emergency Stop switch 63... External communication connector 64... Power switch 65... Display 70a... Uninterruptible power supply 70b... Control unit 70c... Transformer 100... Outer door 100a... A layer 100b... B layer 110... Inner door 122... Container holder 123... Slope 124... Needle unit placement part 125... Drug extraction needle 126... Venting needle 127... Needle holders 127a, 427a... First needle holders 127b, 427b... Second needle holder 128... Needle unit 129... Needle drive mechanism 130, 430... Main boards 131, 431. ... Sub-board 132... Tube holding portion 133... Needle guide portions 134a, 134b... Guide hole 135... Switching member holding portion 136... Syringe holding portion 136a... First syringe holding portion 136b...Second syringe holding section 138...Filter holding section 139,439...Coupling member 142...Syringe driving section 143a, 143b...Plunger fitting section 144...Holding flow path component Portion 146... Flow path switching member holding portions 147a, 147b... Opening 160... Guide path 161... Flow path inlet 162... Flow path outlet 180... Waste liquid bottle 201... 2nd opening 210... Notch area 211... Upper surface 211a... High surface part 211b... Low surface part 211c... First opening 211d... Opening 222... Container holder 228... Needle unit 300, 310... Motor 434a, 434b... Guide holes S1, S2... Shielding area

Claims (11)

A radiopharmaceutical administration device for administering a radiopharmaceutical to a living body,
A container holding portion for holding a shielding container in which the drug container of the radiopharmaceutical is stored,
A configuration attachment portion to which a plurality of flow channel constituent members constituting a part of the flow channel connected to the drug container housed in the container holding part are attached,
A shielding member that covers at least a part of the container holding portion or the component mounting portion to shield the radiation emitted from the radiopharmaceutical.
A device housing that covers at least a portion of the shielding member,
The shielding member has a lower surface portion in which a part of the upper surface in the installation direction is lower than the other portion of the upper surface, and the flow path drawn out from the shielding member is loosely inserted above the lower surface portion. A radiopharmaceutical administration device having a space.   The radiopharmaceutical administration device according to claim 1, wherein the shielding member is provided with a plurality of shielding regions that individually shield the container holding portion and the component mounting portion.   The radiopharmaceutical administration according to claim 1 or 2, further comprising a flow channel guiding part that holds the flow channel between a first opening formed in the shielding member and a second opening formed in the device housing. apparatus.   The radiopharmaceutical administration device according to claim 3, wherein the flow channel guiding unit enables the flow channel to move in the width direction of the device housing.   The radiopharmaceutical administration device according to any one of claims 1 to 4, wherein a part of the flow path is routed upward in the loose insertion space and in a width direction of the device housing. The shielding member has a plurality of shielding walls that form a shielding space, and a shielding door that opens or closes the shielding space,
The shielding door includes an outer door having an outer surface exposed to the outside of the radiopharmaceutical administration device, and an inner door facing an inner surface that is a back surface of the outer door with respect to the outer surface. The radiopharmaceutical administration device according to claim 1.   The constituent mounting portion is provided on the flow passage, and one or a plurality of syringe drive portions that drive a plunger portion of a syringe to extract the radiopharmaceutical from the shielding container through the flow passage. A flow path switching member holding portion holding a flow path switching member to be switched is attached, the inner door covers the flow path switching member holding portion, and the outer door covers the syringe drive portion and the inner door. The radiopharmaceutical administration device according to claim 6, wherein   8. The radiopharmaceutical administration device according to claim 6, wherein the radiation blocking ability of the inner door is higher than the radiation blocking ability of the outer door.   The radiopharmaceutical administration device according to claim 6, wherein the container holding portion is provided on the inner door of the shield door. An extraction needle holding unit that holds an extraction needle that extracts the radiopharmaceutical from the drug container, and a needle unit that detachably holds a ventilation needle holding unit that holds a ventilation needle punctured in the drug container,
The needle unit includes a needle guide portion that moves up and down while holding the extraction needle holding portion and the ventilating needle holding portion such that the extraction needle holding portion and the ventilating needle holding portion are arranged in a front-rear direction intersecting the width direction of the device housing. 10. The radiopharmaceutical administration device according to any one of items 1 to 9.   The needle guide portion is a guide groove that extends in the up-down direction. One of the extraction needle holding portion and the ventilation needle holding portion moves, and the other moves the second guide groove. The radiopharmaceutical administration device according to claim 10, further comprising: and one of the first guide groove and the second guide groove is bent in a direction approaching the other.

Images